

What is your Name?	What is your email?	What keywords would you use to describe your research?	Briefly describe your research:	If you are looking for a collaborator on a project, what skills would be ideal (eg microbiology, biostatistics)
Albert Zhou	albert.zhou@som.umaryland.edu	malaria		statistics, coding, programming
Erin Beasley	erin-beasley@uiowa.edu	infectious disease epidemiology, vector-borne diseases	My lab group conducts field studies with hunting dogs that have visceral leishmaniasis and/or tick-borne diseases to determine epidemiologic and immunologic aspects of the diseases.	
Robin Hilder	rthilder@icloud.com	NTDs, systematic review, quality improvement		
Ayodeji Ogunleye	richiecross@yahoo.com			
Neima Briggs	neima.briggs@yale.edu	Vaccine development; immunology of host-pathogen relationship; parasitology		
Zheyi Teoh	teoh3osu@gmail.com	Epidemiology, Global Health, Arboviruses, Respiratory viruses	Epidemiology of respiratory viruses in young children, Dengue virus	Epidemiology, global health experience
Irene Losada	irene.losada@isglobal.org	Chagas Disease	Chagas disease	data science
Rachel Martin-Blais	Rmartinblais@mednet.UCLA.edu			
adeyemo dayo omodele	thinkerdy@gmail.com	Infectious Diseases	species identification of spoilage organisms and pathogenic bacteria	microbiology
Francis Adjei Osei	francisph1@hotmail.com	Epidemiological studies	Onchocerciasis, non-communicable diseases, infectious diseases	international health
Ben Norton	benbnorton@gmail.com			
Crespo'o Ndiabamoh	Cndiabamoh@gmail.com	TB, Malaria	and AFB beg patients and other infections mimicking TB	Microbiology and immunology.
Jean Moise Kabore	jeanmoise.kabore@swisstph.ch	Malaria, drugs, Innovative, Multiple first line therapies, elimination, ACTs	Piloting multiple artemisinin-based first-line combination therapies (MFTs) as an innovative approach to the management of uncomplicated malaria. Resistance to artemisinin-based combination therapies (ACTs) is the current challenge in malaria control and elimination. We hypothesize that deployment of MFTs can extend the therapeutic life of current ACTs by reducing drug pressure and slowing the spread of resistance without putting lives at risk. The objective of this research project is to evaluate its feasibility, acceptability, and effects on malaria indicators. It will be implemented in 40 health facilities in Burkina Faso.	Biostatistics,
Laia J Vazquez Guillamet	laiajvqll@gmail.com	Global Health	pregnant women and infants from Sub-Saharan Africa	
Katherine Laycock	laycockk@chop.edu	arboviruses, kinetoplastids, tuberculosis, pediatric infections		
Mario	molivera@ins.gov.co	Epidemiology, Health economics, Public health, Parasitology, Tropical medicine	My research focuses on statistical, economic and epidemiological methods to understand the distribution, risk factors, determinants of infectious tropical diseases, the cost of diseases, and the application of these studies to the control of diseases and other health problems. I have worked mainly on vector-borne diseases, such as Chagas disease and malaria.	Microbiology, Molecular biology, field work
R Philip Scheibel	Philscheibel@gmail.com			
Seth Judson	sethjudsonmd@gmail.com	Zoonotic diseases, One Health, Pandemic Preparedness, Planetary Health	I am a physician scientist who investigates emerging zoonotic diseases, particularly hemorrhagic fever viruses and coronaviruses. I also work with international policymakers on pandemic preparedness.	
Keely Johnson	keelyjohnsonmd@gmail.com	Cryptococcus, dengue, TB, COVID	pulmonary critical care outcome in COVID	Biostatistics
Diego Alvarez	diego.alvarez.hernandez@hotmail.com	Antimicrobial resistance; COVID-19; Neglected tropical diseases		
Hannah Steinberg	hannahsteinberg08@gmail.com	Diagnostics, Parasitology, Toxoplasma, Mass Spectrometry	Development of diagnostics for toxoplasmosis in non-traditional biofluids	protein expression, antibody production

Become a participant at <https://forms.gle/nvL8yAZHCKCENVuQ8>